Calithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.com
by Renee Jackson · The Cerbat GemStockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Calithera Biosciences Stock Performance
CALA opened at $0.00 on Friday. Calithera Biosciences has a 12 month low of $0.00 and a 12 month high of $0.12.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.
See Also
- Five stocks we like better than Calithera Biosciences
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors